Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.
diagnosed with PTSD according to DSM-IV or DSM-5 criteria
current treatment at the outpatient facilities of Lev HaSharon Netanya Adult Clin
age between 20 and 60 years
PTSD diagnosis at least one month prior to study inclusion
comorbid major psychiatric disorder, e.g. psychotic disorder, unipolar or bipolar disorder, borderline personality disorder, or active suicidal ideation,
ADHD diagnosis,
significant or severe systematic disease that limits normal activity, e.g. autoimmune disease, AIDS or renal failure,
cardiovascular disease, e.g. hypertension, atrioventricular (AV) block, bradycardia, or conduction disorder,